Genmab and GSK enter lucrative global agreement  

2006.12.20
Danish biotech firm Genmab and GlaxoSmithKline have entered a global agreement to co-develop and commercialise HuMax-CD20
Danish biotech firm Genmab and GlaxoSmithKline (GSK) have entered a global agreement to co-develop and commercialise HuMax-CD20, a fully human monoclonal antibody in late stage development for the treatment of chronic lymphocytic leukaemia and follicular non-Hodgkin's lymphoma, and in phase II for rheumatoid arthritis.
 
The total potential value of the agreement in case of full commercial success could exceed DKK 12 bn (USD 2.2 bn) including the initial licence fee and equity purchase, milestone payments and expected development, commercial manufacturing and commercialisation costs, says Genmab.
 
Lisa N. Drakeman, managing director of Genmab comments: "With this collaboration, HuMax-CD20 will benefit from GSK's enormous strength in development, sales and marketing. We are looking forward to the collaboration and to work together on optimising the value of this product which potentially could benefit many patients with various diseases."
 
Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, rheumatoid arthritis, infectious diseases and other inflammatory conditions. Genmab currently has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen.
 
Link > Genmab

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×